Pre-operative use of anti-TNF-a agents and the risk of post-operative complications in patients with Crohn's disease - a nationwide cohort study

被引:66
作者
Norgard, B. M. [1 ,2 ]
Nielsen, J. [1 ,2 ]
Qvist, N. [3 ,4 ]
Gradel, K. O. [1 ,2 ]
de Muckadell, O. B. Schaffalitzky [5 ,6 ]
Kjeldsen, J. [5 ,6 ]
机构
[1] Univ So Denmark, Ctr Natl Clin Databases, Odense Univ Hosp, DK-5000 Odense C, Denmark
[2] Univ So Denmark, Res Unit Clin Epidemiol, Inst Clin Res, Odense C, Denmark
[3] Univ So Denmark, Dept Surg Gastroenterol A, Odense Univ Hosp, Odense C, Denmark
[4] Univ So Denmark, Res Unit Surg Gastroenterol, Inst Clin Res, Odense C, Denmark
[5] Univ So Denmark, Dept Med Gastroenterol S, Odense Univ Hosp, Odense C, Denmark
[6] Univ So Denmark, Res Unit Med Gastroenterol, Inst Clin Res, Odense C, Denmark
关键词
INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; INFLIXIMAB THERAPY; ABDOMINAL-SURGERY; SHORT-TERM; VALIDATION; MORBIDITY; RESECTION; FUNGEMIA; EFFICACY;
D O I
10.1111/apt.12159
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background A possible negative role of pre-operative use of antitumour necrosis factor-alpha (anti-TNF-a) agents on post-operative outcomes in Crohn's disease (CD) patients is still debated. Aim To examine the impact of pre-operative anti-TNF-a agents on post-operative outcomes 30 and 60days after CD surgery in a nationwide Danish cohort. Outcomes were death, reoperation, anastomosis leakage, intra-abdominal abscess and bacteraemia. Methods We identified all patients having surgical procedures from 1 January 2000 to 31 December 2010 (n=2293). Patients were classified according to use of anti-TNF-a agents within 12weeks before surgery (exposed) or not (unexposed). Outcomes were obtained from nationwide registries and a bacteraemia registry. Sub-analyses were performed for bacteraemia and for impact of pre-operative timing of anti-TNF-a agents. Results Among surgical procedures for CD, 214 were exposed and 2079 were not. We found no increased relative risks of death or abscess drainage 30 or 60days after follow-up. Among exposed, 7.5% had a reoperation within 30days vs. 8.6% among unexposed, adjusted odds ratio (OR)=0.92, 95% confidence interval (CI): 0.521.63. Among exposed, 3.8% had an anastomosis leakage within 30days after surgery vs. 2.8% among unexposed, adjusted OR=1.33, 95% CI: 0.593.02. No further cases of anastomosis leakages appeared within 60days. Sub-analyses indicated no increased risk of bacteraemia after 30days and no increased risks when anti-TNF-a agents were given =14days before surgery. Conclusion We found no significantly increased relative risks of post-operative complications after use of anti-TNF-a agents either 12weeks or =14days before surgery for Crohn's disease.
引用
收藏
页码:214 / 224
页数:11
相关论文
共 35 条
[1]  
Andersen TF, 1999, DAN MED BULL, V46, P263
[2]   Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients [J].
Appau, Kweku A. ;
Fazio, Victor W. ;
Shen, Bo ;
Church, James M. ;
Lashner, Bret ;
Remzi, Feza ;
Brzezinski, Aaron ;
Strong, Scott A. ;
Hammel, Jeffrey ;
Kiran, Ravi P. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (10) :1738-1744
[3]   National Surveillance of Fungemia in Denmark (2004 to 2009) [J].
Arendrup, Maiken Cavling ;
Bruun, Brita ;
Christensen, Jens Jorgen ;
Fuursted, Kurt ;
Johansen, Helle Krogh ;
Kjaeldgaard, Poul ;
Knudsen, Jenny Dahl ;
Kristensen, Lise ;
Moller, Jens ;
Nielsen, Lene ;
Rosenvinge, Flemming Schonning ;
Roder, Bent ;
Schonheyder, Henrik Carl ;
Thomsen, Marianne K. ;
Truberg, Kjeld .
JOURNAL OF CLINICAL MICROBIOLOGY, 2011, 49 (01) :325-334
[4]  
Brzezinski A, 2002, GASTROENTEROLOGY, V122, pA617
[5]   Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates? [J].
Canedo, J. ;
Lee, S. -H. ;
Pinto, R. ;
Murad-Regadas, S. ;
Rosen, L. ;
Wexner, S. D. .
COLORECTAL DISEASE, 2011, 13 (11) :1294-1298
[6]  
Catassi C, 2000, SCAND J GASTROENTERO, V35, P732
[7]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[8]   Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy [J].
Colombel, JF ;
Loftus, EV ;
Tremaine, WJ ;
Pemberton, JH ;
Wolff, BG ;
Young-Fadok, T ;
Harmsen, WS ;
Schleck, CD ;
Sandborn, WJ .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (05) :878-883
[9]   Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease [J].
Cornillie, F ;
Shealy, D ;
D'Haens, G ;
Geboes, K ;
Van Assche, G ;
Ceuppens, J ;
Wagner, C ;
Schaible, T ;
Plevy, SE ;
Targan, SR ;
Rutgeerts, P .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (04) :463-473
[10]   Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease [J].
El-Hussuna, Alaa ;
Andersen, Jens ;
Bisgaard, Thue ;
Jess, Per ;
Henriksen, Mads ;
Oehlenschlager, Jacob ;
Thorlacius-Ussing, Ole ;
Olaison, Gunnar .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2012, 47 (06) :662-668